Teva Pharm Stock Price, News & Analysis

Teva Pharmaceuticals (NYSE:TEVA) reported strong Q2 2025 results, marking its 10th consecutive quarter of year-over-year growth. The company achieved revenues of $4.2 billion and increased its 2025 outlook for key innovative products. Notable highlights include AUSTEDO revenues of $498 million (+19%), AJOVY reaching $155 million (+31%), and UZEDY at $54 million (+120%).

The company reported GAAP EPS of $0.24 and Non-GAAP EPS of $0.66, a 9% increase year-over-year. Free cash flow grew 47% to $476 million. Teva remains on track to achieve a 30% operating profit margin by 2027 through its transformation programs, targeting ~$700 million in net savings.

Teva Pharmaceutical Industries (NYSE:TEVA) has released its Q2 2025 Aide Memoire document, which is now accessible on the company's investor relations website. The document serves as a financial modeling aid for analysts and investors, incorporating historical performance data, management's business outlook, and selected third-party information.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has scheduled its second quarter 2025 financial results announcement for July 30, 2025. The company will release its financial results at 7:00 a.m. ET, followed by a conference call and live webcast at 8:00 a.m. ET.

Investors and interested parties can participate by registering in advance to obtain local or toll-free phone numbers. The webcast will be accessible through Teva's investor relations website, with a replay available within 24 hours after the call.

Teva Pharmaceuticals (TEVA) announced final results from its two-year PEARL Phase 4 real-world study of AJOVY (fremanezumab) for migraine prevention. The study, presented at EAN 2025 Congress, demonstrated sustained effectiveness in reducing migraine frequency, duration, and severity in both chronic and episodic migraine patients. The study of 1,140 patients showed that over 66% of episodic migraine patients and 51.6% of chronic migraine patients achieved ≥50% reduction in Monthly Migraine Days (MMD) during the first 6 months, with benefits sustained over 24 months. Notable outcomes include high injection adherence rates (~90%) and strong study completion rate (75%). The drug maintained a favorable safety and tolerability profile throughout the study period, consistent with previous trials.

Teva Pharmaceutical (NYSE: TEVA) and Fosun Pharma have formed a strategic partnership to develop TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy currently in Phase 1 trials for various cancers including melanoma. Under the agreement, Fosun Pharma receives exclusive rights to develop, manufacture, and commercialize TEV-56278 in mainland China, Hong Kong, Macau, Taiwan, and select Southeast Asian countries, while Teva maintains rights for the rest of the world. TEV-56278, developed using Teva's ATTENUKINE technology, represents a novel approach to cancer immunotherapy by selectively delivering IL-2 to PD-1+ T cells, potentially offering high efficacy and low toxicity. The partnership aims to accelerate clinical data generation, with Teva leveraging Fosun Pharma's data in other regions.

Teva Pharmaceutical announced the pricing and early acceptance results of its debt tender offers for various series of outstanding notes. The company will purchase notes across three pools with tender caps of $1.55B, $350M, and $400M respectively. Notes with Acceptance Priority Level 4 will be accepted in full, while those with levels 1, 2, and 5 will be subject to proration factors of 60.74999%, 39.4586%, and 36.663%. Notes with Priority Levels 3 and 6 will not be accepted. The settlement is expected on June 5, 2025, with holders receiving the Total Consideration including Early Tender Premium. The offers were supported by Teva's recent $2.3B senior notes offering on May 28, 2025.

Teva Pharmaceutical announced early tender results for its debt tender offers, including increases to tender pool caps and total maximum amount. The company increased Pool 2 Tender Cap from $250M to $350M, Pool 3 Tender Cap from $200M to $400M, and Total Maximum Amount from $2.25B to $2.3B. The tender offers cover multiple series of senior notes with various interest rates and maturities. Teva expects to accept notes worth approximately $2.3B for purchase, with settlement scheduled for June 5, 2025. The tender offers are funded through proceeds from a recent public offering of debt securities and cash on hand. This move is part of Teva's strategy to manage and optimize its debt capital structure and extend its debt maturity profile.

Teva Pharmaceuticals revealed concerning findings about tardive dyskinesia (TD) treatment in long-term care facilities. The study showed that over 50% of LTC residents with TD don't receive standard care treatment, and 25% receive no treatment at all. Among residents on antipsychotic drugs, 5.6% were diagnosed with extrapyramidal syndrome while only 1.1% received specific TD diagnosis. The research, analyzing ~700,000 residents on antipsychotic drugs and ~35,000 on Reglan, found mood disorders as the most common underlying condition (68% and 54% respectively). Common comorbidities included dementia, chronic pulmonary disease, and congestive heart failure. Less than half of TD patients received the recommended VMAT2 inhibitor treatment, with most receiving non-FDA approved treatments like benztropine.

Teva Pharmaceuticals presented significant data for its schizophrenia treatment portfolio at the 2025 Psych Congress Elevate Annual Meeting. Real-world studies of UZEDY (risperidone) showed superior outcomes compared to oral treatments, including lower relapse rates (9.0% vs 15.4-16.8%), better adherence (71.3% vs 52.8%), and reduced healthcare costs ($18,796 vs $26,376). UZEDY patients also experienced fewer hospital visits and shorter stays. Additionally, Teva's investigational drug TEV-'749 (olanzapine) demonstrated promising Phase 3 SOLARIS trial results, with no post-injection delirium/sedation syndrome (PDSS) reported after 3,400+ injections, while meeting primary efficacy endpoints across all dosing groups with significant PANSS score improvements versus placebo.